TimesSquare Capital Management LLC Has $76.41 Million Stock Position in argenx SE (NASDAQ:ARGX)

TimesSquare Capital Management LLC boosted its stake in shares of argenx SE (NASDAQ:ARGX) by 13.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 124,245 shares of the company’s stock after buying an additional 14,755 shares during the period. argenx makes up approximately 1.1% of TimesSquare Capital Management LLC’s holdings, making the stock its 26th biggest holding. TimesSquare Capital Management LLC owned 0.21% of argenx worth $76,411,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Global Retirement Partners LLC raised its holdings in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. Venturi Wealth Management LLC acquired a new stake in argenx during the 4th quarter worth approximately $66,000. Nkcfo LLC acquired a new stake in argenx during the 4th quarter worth approximately $68,000. Advisors Preferred LLC acquired a new stake in argenx during the 4th quarter worth approximately $73,000. Finally, Cromwell Holdings LLC grew its stake in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Performance

ARGX opened at $639.00 on Wednesday. argenx SE has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The company has a market capitalization of $38.83 billion, a P/E ratio of -726.14 and a beta of 0.58. The stock has a fifty day moving average of $640.74 and a 200-day moving average of $584.63.

Analysts Set New Price Targets

Several brokerages have recently weighed in on ARGX. William Blair raised shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Guggenheim raised their price target on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and set a $700.00 price target (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their price target for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, Oppenheimer reissued an “outperform” rating and issued a $675.00 target price (up from $646.00) on shares of argenx in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.